Identification of Markers (Klotho-FGF23 Axis) as Determinant in the Evolution of Arterial Stiffness During the First Year of Renal Transplant
Launched by HOPITAL FOCH · Oct 28, 2016
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Man or woman 18 to 70 years old
- • Renal transplant
- • Dead donor or alive donor
- • Immunosuppression including a calcineurin inhibitor
- • Written consent
- Exclusion Criteria:
- • MultipleTransplant
- • Morbid Obesity (Body Mass Index (BMI)\> 40 kg/m2 sc)
- • Cardiac Arrhythmia
- • Lower limbs occlusive arterial disease
- • Impossibility to understand the information form
About Hopital Foch
Hospital Foch is a leading healthcare institution located in Suresnes, France, renowned for its commitment to innovative medical research and patient-centered care. As a prominent clinical trial sponsor, Hospital Foch actively engages in the development of new therapeutic approaches across various medical disciplines, facilitating cutting-edge studies that aim to enhance treatment outcomes and improve patient quality of life. With a multidisciplinary team of experienced researchers and healthcare professionals, the hospital fosters a collaborative environment that prioritizes ethical standards and scientific rigor, ensuring the highest quality in clinical trial execution and patient safety.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Suresnes, , France
Paris, , France
Patients applied
Trial Officials
Michel Delahousse, MD
Principal Investigator
Hopital Foch
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials